Blog Archives

Schwere Nebenwirkungen: Das MS-Arzneimittel Daclizumab (Zinbryta) weltweit vom Markt genommen

02. März 2018 – Daclizumab (Zinbryta) wurde im Mai 2016 in den USA, im Juli 2016 in der Europäischen Union (EU) und im Januar 2017 auch in der Schweiz zur Behandlung der schubförmig auftretenden Multiplen Sklerose auf dem Markt zugelassen. Daclizumab (Zinbryta) ist ein therapeutischer humanisierter monoklonaler Antikörper gegen den Interleukin-2-Rezeptor (genauer: gegen die α-Kette CD25),

Read more ›

Tags: , , , , , , , , ,

Natalizumab (Tysabri)’s Risiko für PML

natali-ii

20. September 2016 – Swissmedic, das Schweizer Heilmittelinstitut, kommuniziert in der Form einer sog. Health Professional Communication (HPC) aktualisierte Massnahmen um dem Risiko von progressiv multifokaler Leukoencephalopathie (PML) unter Therapie mit Natalizumab (Tysabri) entgegenzuwirken.

Read more ›

Tags: , , , ,

BfArM: Strengere kardiovaskuläre Überwachung zu Beginn der Therapie mit Fingolimod [Gilenya] bei Patienten mit schubförmig-remittierend verlaufender Multipler Sklerose

27. Januar 2012 – Das BfArM hat heute mitgeteilt, dass ein “Rote Hand Brief” betreffend Fingolimod [Gilenya] mit untenstehendem Wortlaut von der Firma Novartis Pharma versandt wurde.

________________________

Novartis möchte Sie über wichtige zusätzliche Empfehlungen zu mit Fingolimod [Gilenya] informieren. Diese betreffen eine intensivere Überwachung der kardiovaskulären Funktionen innerhalb der ersten 6 Stunden nach Behandlungsbeginn mit Fingolimod [Gilenya],

Read more ›

Tags: , , , ,

thasso: zustände

thasso: kurzmitteilungen

thasso post: magazin

View my Flipboard Magazine.

thasso: kategorien

thasso: archive

thasso: einfacher chat

You must be a registered user to participate in this chat.

  • New tumor-driving mutations discovered in the under-explored regions of the cancer genome January 18, 2020
    In an unprecedented pan-cancer analysis of whole genomes, researchers at the Ontario Institute for Cancer Research (OICR) have discovered new regions of non-coding DNA that, when altered, may lead to cancer growth and progression.
  • Loss of function in key Y-chromosome genes increases cancer risk in men January 17, 2020
    Numerous studies have shown that men are more susceptible to cancer than women; however, the reason for this difference remains poorly understood. A new study by researchers from the Barcelona Institute for Global Health (ISGlobal) has identified a key biological mechanism that puts men at higher risk of cancer: loss of function in certain genes […]
  • Why we differ in our ability to fight off gut infections January 17, 2020
    Τhe ability of the immune system to fight off bacterial, viral and other invading agents in the gut differs between individuals. However, the biological mechanism by which this happens is not well understood, but at least part of this difference may be explained by genetic factors.
  • Low doses of radiation used in medical imaging lead to mutations in cell cultures January 16, 2020
    Common medical imaging procedures use low doses of radiation that are believed to be safe. A new study, however, finds that in human cell cultures, these doses create breaks that allow extra bits of DNA to integrate into the chromosome. Roland Kanaar and Alex Zelensky of Erasmus University Medical Center and Oncode Institute and colleagues […]
  • Progress in unraveling the mystery of the genomics of Parkinson's disease January 16, 2020
    The International Parkinson Disease Genomics Consortium (IPDGC) has now been in existence for ten years. In an article published in the Journal of Parkinson's Disease the consortium reviews the progress made over the past decade in the genomics of Parkinson's disease (PD) and related disorders including Lewy body diseases, progressive supranuclear palsy, and multiple system […]
Top